Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors

Emergent BioSolutions Secures New ACAM2000 Biodefense Contract

Emergent Gets $52.7 Million Contract Modification From US Government

Emergent BioSolutions awarded $52.7M contract modification

Emergent Biosolutions Secures Contract Modification Valued at Approximately $52.7 Million for Acam2000® (smallpox and Mpox (vaccinia) Vaccine, Live) from the U.S. Government

Emergent Biosolutions - Contract Modification Under Existing 10-year Contract with Aspr

Tonix Pharmaceuticals - Enrolls First Patient in Phase 2 Horizon Study of Tnx-102 Sl for Mdd - SEC Filing

Tonix Pharmaceuticals - Primary Endpoint is Change in Madrs Total Score at Week 6 - SEC Filing

Tonix Enrolls First Patient in Phase 2 Trial of Tnx-102 SL for Major Depressive Disorder

Viatris Says Phase 3 Japan Trial of Vr-205 in Iga Nephropathy Meets Primary Endpoint with 33.75% UPCR Drop

Viatris - Targets Japanese Nda Submission for Vr-205 by End of 2026

Viatris - Vr-205 Meets Primary and Key Secondary Endpoints and is Well Tolerated

Viatris Announces Positive Top-line Results from Phase 3 Study of Vr-205 in Japanese Adults with Primary Immunoglobulin a Nephropathy

Viatris - Vr-205 Shows 33.75% Reduction in Upcr at 9 Months in Phase 3 Study

Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts

Viatris Interim CFO Paul Campbell Sells 50,076 Shares for $809,927.6

Moderna Inc. Stock Climbs 12.6%, Outperforms Peers

NASDAQ Trade Halt Continues Volatility Trading Pause at 11:39 Am

Aethlon Medical Study Flags Long COVID Biomarker, Supports Hemopurifier Evaluation

Virax Biolabs Group Ltd trading halted, news pending